Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer?

Journal of Urology

Volumn 180, Issue 3, 2008, Pages 1146-1153

  Kassouf, Wassim ^a   Brown, Gordon A ^b   Black, Peter C ^b   Fisher, Mark B ^b   Inamoto, Teruo ^b   Luongo, Tony ^b   Gallagher, David ^b   Bar Eli, Menashe ^b   McConkey, David J ^b   Adam, Liana ^b   Dinney, Colin P N ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

angiogenesis inhibitors; carcinoma; gefitinib; transitional cell; urinary bladder; vascular endothelial growth factor

Indexed keywords

GEFITINIB; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 48649093532     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.05.001     Document Type: Article

References (18)

1. Crew J.P. Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer. Eur Urol 35 (1999) 2
2. Slaton J.W., Millikan R., Inoue K., Karashima T., Czerniak B., Shen Y., et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 171 (2004) 570
3. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995) 183
4. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60 suppl. (2000) 25
5. Mendelsohn J., and Dinney C.P. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J Urol 165 (2001) 1152
6. Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7 (2001) 1459
7. Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B., Hicklin D., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5 (1999) 257
8. Paez J.G., Janne P.A., Lee J.C., Tracey S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497
9. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129
10. Kassouf W., Dinney C.P., Brown G., McConkey D., Diehl A., Bar-Eli M., et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 65 (2005) 10524
11. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4
12. Zachary I., and Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 49 (2001) 568
13. Li C.Y., Shan S., Huang Q., Braun R., Lanzen J., Hu K., et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2000) 143
14. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669
15. Ellis L.M., Staley C.A., Liu W., Fleming R.Y., Parikh N.U., Bucana C.D., et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273 (1998) 1052
16. Maity A., Pore N., Lee J., Solomon D., and O'Rourke D.M. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60 (2000) 5879
17. Bouvet M., Ellis L.M., Nishizaki M., Fujiwara T., Liu W., Bucana C.D., et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58 (1998) 2288
18. Blehm K.N., Spiess P.E., Bondaruk J.E., Dujka M.E., Villares G.J., Zhao W.J., et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12 (2006) 4671